Merus Stock Price, News & Analysis

Merus N.V. (MRUS) announced interim data from the phase 1/2 eNRGy trial of its bispecific antibody, Zeno, aimed at treating NRG1+ cancer. Key findings include a 34% overall response rate in 79 evaluable patients, with a median duration of response at 9.1 months. Tumor reduction was observed in 70% of patients, and Zeno was noted to be well-tolerated. These results position Zeno as a potential new standard of care. An investor call is scheduled for June 5, 2022 to discuss these findings further.

Merus N.V. (Nasdaq: MRUS) will participate in a fireside chat at the Jefferies Healthcare Conference on June 10, 2022, at 12:45 p.m. ET. Bill Lundberg, M.D., the President and CEO, will represent the clinical-stage oncology company known for developing innovative multispecific antibodies, including Biclonics® and Triclonics®. A webcast of the event can be accessed on the Company's Investors page, and an archived version will be available post-event.

Merus N.V. (Nasdaq: MRUS) announced positive interim results from its phase 1/2 eNRGy trial of zenocutuzumab (Zeno) for NRG1+ cancers. The data shows a robust 34% overall response rate and a median duration of response of 9.1 months. The treatment is well-tolerated, with efficacy observed across multiple NRG1+ tumor types. An oral presentation is scheduled for June 5, 2022, at ASCO, with an investor call also planned the same day to discuss these findings. The trial focuses on safety and anti-tumor activity of Zeno monotherapy in various NRG1+ cancers.

Merus N.V. (Nasdaq: MRUS) announced that its CEO, Bill Lundberg, will present at the H.C. Wainwright Global Investment Conference. This presentation will occur on May 24, 2022, with a live webcast available at 7:00 a.m. ET on the company's Investors page. An archived version will be accessible for a limited time following the event.

Merus focuses on developing innovative full-length multispecific antibodies, including its proprietary Biclonics® and Triclonics® therapies, which have demonstrated promising features in clinical studies.

Merus N.V. (Nasdaq: MRUS) reported its Q1 2022 financial results, indicating a total revenue increase to $11.7 million from $8.4 million in Q1 2021, driven by collaboration revenue growth. The company ended Q1 with cash reserves of $384.3 million, down from $430.8 million at year-end 2021. Net loss for the quarter was $18.9 million, slightly improving from a loss of $10.2 million year-over-year. Merus is excited about its upcoming ASCO presentation on Zenocutuzumab, highlighting its ongoing clinical trials and pipeline growth. Cash runway is expected to last beyond 2024.

Merus N.V. (Nasdaq: MRUS) announced that an abstract showcasing interim clinical data for zenocutuzumab (Zeno), a bispecific antibody targeting NRG1+ cancer, has been selected for oral presentation at the 2022 ASCO Annual Meeting in Chicago from June 3-7, 2022. The presentation, titled 'Efficacy and safety of zenocutuzumab,' will take place on June 5. Merus is currently conducting the phase 1/2 eNRGy trial and will discuss updated interim data during a conference call on the same day.

Merus N.V. (Nasdaq: MRUS) announced the publication of a preclinical report on its bispecific antibody, petosemtamab (Peto, MCLA-158), in Nature Cancer. The report highlights Peto's potent growth inhibition of colorectal cancer organoids and its unique mechanism that triggers EGFR degradation in LGR5-expressing organoids. Peto shows promising results compared to cetuximab, with superior growth inhibition in KRAS mutant CRC models. The company is currently enrolling patients for a Phase 1 trial and plans a clinical update in the second half of 2022.

Merus N.V. (MRUS) announced promising preclinical data for MCLA-129, highlighting its ability to promote Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cell-Mediated Phagocytosis (ADCP) in non-small cell lung cancer (NSCLC). The findings, which show MCLA-129's significant inhibition of growth in a patient-derived EGFR exon20 insertion tumor model, will be presented at the AACR Annual Meeting 2022. Currently, MCLA-129 is in a phase 1/2 clinical trial, with updates anticipated in the second half of 2022.

Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced that its CEO, Bill Lundberg, M.D., will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on April 13 from 10:15-10:55 a.m. ET. The event will be accessible via a live webcast on the Company's investor page, with an archived version available afterward. Merus specializes in developing innovative multispecific antibodies, including its unique Biclonics® and Triclonics®, which show promise in clinical studies.